New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
InterCure Ltd.
INCR
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

79M

Drug Manufacturers - Specialty & Generic

1.73USD
Shape-0.01 ( -0.57%)
favorite-chart

Relative Strenght

96
favorite-chart

Volume Buzz

-31%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

53%
OverviewChart

Quote Panel

Shape
Updated October 21, 2024
1W -4.95 % 1M -1.70 % 3M -29.67 % 1Y 55.86 %

Key Metrics

Shape

  • Market Cap

    79.17M

  • Shares Outstanding

    45.77M

  • Share in Float

    25.67M

  • Dividende

    0

  • Earning Date

    No Data

  • Price Target

    1.73

  • Average Volume

    25467

  • Beta

    0.058

  • Range

    0.99-3.72

  • Industry

    Drug Manufacturers - Specialty & Generic

  • Website

    https://www.intercure.co

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

1.12x

P/S Ratio

0.69x

P/B Ratio

0.3

Debt/Equity

-24.1%

Net Margin

$-0.4

EPS

How INCR compares to sector?

P/E Ratio

INCR

-5x

AYRWF -1x
VRNOF -10x
TLLTF 0x
LOWLF 0x
VEXTF -5x

Relative Strength

Shape

INCR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$1B

Shape1851%

2024-Revenue

0

$124M

Shape-1817%

2024-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Canaccord Genuity

upgrade

Previous: Not converted

2022-05-17

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

-17%

0.1
vs 0.12

Q3.22

arrow
arrow

+600%

0.05
vs -0.01

Q4.22

arrow
arrow

+316%

0.05
vs -0.02

Q1.23

arrow
arrow

-91%

0.01
vs 0.11

Q2.23

arrow
arrow

-70%

0.03
vs 0.1

Q3.23

arrow
arrow

N/A

0.05
vs 0.05

Q4.23

arrow
arrow

N/A

-0.21
vs 0.05

Q1.24

arrow
arrow

-59%

0
vs 0.01

Q2.24

arrow
arrow

-87%

0
vs 0.03

Q3.24

arrow
arrow

+11573%

5.84
vs 0.05

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

+111%

95.3M  vs 45.2M

Q3.22

arrow
arrow

+63%

100.6M  vs 61.7M

Q4.22

arrow
arrow

+33%

105.6M  vs 79.7M

Q1.23

arrow
arrow

+22%

106.2M  vs 87.2M

Q2.23

arrow
arrow

+8%

102.4M  vs 95.3M

Q3.23

arrow
arrow

-27%

73.5M  vs 100.6M

Q4.23

arrow
arrow

-30%

73.5M  vs 105.6M

Q1.24

arrow
arrow

-41%

62.9M  vs 106.2M

Q2.24

arrow
arrow

-39%

62.9M  vs 102.4M

Q3.24

arrow
arrow

-3%

71.5M  vs 73.5M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+1%

0.01
vs 0.03

Q4.22

arrow
arrow

+1%

0.01
vs 0.01

Q1.23

arrow
arrow

+0%

0
vs 0.01

Q2.23

arrow
arrow

+1%

0.01
vs 0

Q3.23

arrow
arrow

-7%

-0.07
vs 0.01

Q4.23

arrow
arrow

-7%

-0.07
vs -0.07

Q1.24

arrow
arrow

+0%

0
vs -0.07

Q2.24

arrow
arrow

+0%

0
vs 0

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

18

18
vs 16

13%

Q4.22

arrow
arrow

16

16
vs 18

-11%

Q1.23

arrow
arrow

18

18
vs 16

13%

Q2.23

arrow
arrow

19

19
vs 18

6%

Q3.23

arrow
arrow

22

22
vs 19

16%

Q4.23

arrow
arrow

18

18
vs 22

-18%

Q1.24

arrow
arrow

20

20
vs 18

11%

Q2.24

arrow
arrow

20

20
vs 20

NA

Earnings Growth

Latest News

INCR

seekingalpha.com

3 hours ago

InterCure: A Cannabis Industry Leader Still Flying Under The Radar
INCR

businesswire.com

6 hours ago

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
INCR

businesswire.com

8 hours ago

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
INCR

businesswire.com

8 hours ago

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
INCR

benzinga.com

14 hours ago

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
INCR

globenewswire.com

18 hours ago

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

New Feature Coming Soon, Stay Tuned!

ShapeShape